Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ganwei (also known as HepatoKeeper) is a botanical dietary supplement and herbal extract developed by Taipei City Hospital for the treatment of non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD). It is a multi-ingredient formulation containing extracts from *Schisandra chinensis*, *Paeonia lactiflora*, and *Punica granatum*. The primary mechanism of action involves the induction of Glycine N-methyltransferase (GNMT) expression, a multifunctional protein that plays a regulatory role in liver carbohydrate and lipid metabolism and is typically downregulated in NAFLD tissues. In clinical trials, Ganwei has been evaluated both as a monotherapy and in combination with metformin, demonstrating significant improvements in liver steatosis and fibrosis as measured by FibroScan CAP and kPa scores.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ganwei.